Design and synthesis of Meldrum's acid based 7-azaindole anchored 1,2,3-triazole hybrids as anticancer agents†

IF 3.597 Q2 Pharmacology, Toxicology and Pharmaceutics
MedChemComm Pub Date : 2024-03-11 DOI:10.1039/D4MD00015C
Murali Krishna Vanga, Rambabu Bhukya, Vishnu Thumma, S. S. S. S. Sudha Ambadipudi, V. Lakshma Nayak, Sai Balaji Andugulapati and Vijjulatha Manga
{"title":"Design and synthesis of Meldrum's acid based 7-azaindole anchored 1,2,3-triazole hybrids as anticancer agents†","authors":"Murali Krishna Vanga, Rambabu Bhukya, Vishnu Thumma, S. S. S. S. Sudha Ambadipudi, V. Lakshma Nayak, Sai Balaji Andugulapati and Vijjulatha Manga","doi":"10.1039/D4MD00015C","DOIUrl":null,"url":null,"abstract":"<p >A series of Meldrum's acid, 7-azaindole and 1,2,3-triazole hybrids were synthesized and evaluated for their <em>in vitro</em> anticancer activity against five different cancer cell lines <em>viz.</em> MCF-7 (breast cancer), HeLa (cervical cancer), DU-145 (prostate cancer), HepG2 (liver cancer) and K562 (myelogenous leukemia cell). Among the series, compound <strong>6b</strong> containing a 4-methyl substitution showed potent activity against HeLa cell line. Cell cycle analysis revealed that compound <strong>6b</strong> induced cell cycle arrest at the G2/M phase and induced apoptosis. Apoptotic activity was further confirmed by Hoechst staining and Annexin V-FITC assay. Compound <strong>6b</strong> has been found to exhibit higher activity in all four cell lines, with IC<small><sub>50</sub></small> values of 6.67 ± 0.39 μM, 4.44 ± 0.32 μM, 12.38 ± 0.51 μM and 9.97 ± 0.25 μM against MCF-7, HeLa, DU-145 and HepG2 cell lines respectively. Compounds <strong>6m</strong> (9.68 ± 0.10 μM) and <strong>6n</strong> (9.52 ± 0.38 μM), which have dimethoxy and trimethoxy substitutions, respectively, have demonstrated significant anticancer activity against HeLa cells compared to the other cells. The molecular docking study of ligand <strong>6b</strong> against the crystal structure of EGFR and Mcl-1 scored notable binding energy values and displayed important interactions like H-bond, π–cation and other hydrophobic interactions.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 5","pages":" 1709-1721"},"PeriodicalIF":3.5970,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2024/md/d4md00015c","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

A series of Meldrum's acid, 7-azaindole and 1,2,3-triazole hybrids were synthesized and evaluated for their in vitro anticancer activity against five different cancer cell lines viz. MCF-7 (breast cancer), HeLa (cervical cancer), DU-145 (prostate cancer), HepG2 (liver cancer) and K562 (myelogenous leukemia cell). Among the series, compound 6b containing a 4-methyl substitution showed potent activity against HeLa cell line. Cell cycle analysis revealed that compound 6b induced cell cycle arrest at the G2/M phase and induced apoptosis. Apoptotic activity was further confirmed by Hoechst staining and Annexin V-FITC assay. Compound 6b has been found to exhibit higher activity in all four cell lines, with IC50 values of 6.67 ± 0.39 μM, 4.44 ± 0.32 μM, 12.38 ± 0.51 μM and 9.97 ± 0.25 μM against MCF-7, HeLa, DU-145 and HepG2 cell lines respectively. Compounds 6m (9.68 ± 0.10 μM) and 6n (9.52 ± 0.38 μM), which have dimethoxy and trimethoxy substitutions, respectively, have demonstrated significant anticancer activity against HeLa cells compared to the other cells. The molecular docking study of ligand 6b against the crystal structure of EGFR and Mcl-1 scored notable binding energy values and displayed important interactions like H-bond, π–cation and other hydrophobic interactions.

Abstract Image

设计和合成基于 Meldrum's 酸的 7-氮杂吲哚锚定 1,2,3- 三唑杂环作为抗癌剂
研究人员合成了一系列梅氏酸、7-氮杂吲哚和 1,2,3-三唑杂化物,并评估了它们对五种不同癌细胞系(即 MCF-7(乳腺癌)、HeLa(宫颈癌)、DU-145(前列腺癌)、HepG2(肝癌)和 K562(骨髓性白血病细胞)的体外抗癌活性。在这一系列化合物中,含有 4-甲基替代物的化合物 6b 对 HeLa 细胞株具有强效活性。细胞周期分析表明,化合物 6b 能诱导细胞周期停滞在 G2/M 期,并诱导细胞凋亡。细胞凋亡活性通过 Hoechst 染色和 Annexin V-FITC 检测得到进一步证实。化合物 6b 在所有四种细胞系中都表现出较高的活性,对 MCF-7、HeLa、DU-145 和 HepG2 细胞系的 IC50 值分别为 6.67 ± 0.39 μM、4.44 ± 0.32 μM、12.38 ± 0.51 μM 和 9.97 ± 0.25 μM。化合物 6m(9.68 ± 0.10 μM)和 6n(9.52 ± 0.38 μM)分别具有二甲氧基和三甲氧基取代,与其他细胞相比,对 HeLa 细胞具有显著的抗癌活性。配体 6b 与表皮生长因子受体(EGFR)和 Mcl-1 晶体结构的分子对接研究得出了显著的结合能值,并显示出 H 键、π-阳离子和其他疏水相互作用等重要的相互作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
MedChemComm
MedChemComm BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
CiteScore
4.70
自引率
0.00%
发文量
0
审稿时长
2.2 months
期刊介绍: Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry. In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信